Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
12:00pm, Tuesday, 21'st Feb 2023 GlobeNewswire Inc.
If approved, pozelimab would be the first and only treatment for those living with CHAPLE
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
5 Least-Hurt Biotech ETFs of the Last Week
06:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
5 Least-Hurt Biotech ETFs of the Last Week
02:18pm, Wednesday, 15'th Feb 2023
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)
03:42pm, Tuesday, 14'th Feb 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) SVB Securities Global Biopharma Conference February 14, 2023 9:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development
2 Top Healthcare Stocks Defying the Bear Market
03:00pm, Tuesday, 14'th Feb 2023 The Motley Fool
These companies have impeccable long-term investment theses.
2 Top Healthcare Stocks Defying the Bear Market
10:00am, Tuesday, 14'th Feb 2023
These companies have impeccable long-term investment theses.
2 Biotech Stocks That Could Help Set You Up for Life
06:13pm, Saturday, 11'th Feb 2023 The Motley Fool
The two companies have seen similar share growth over the past year.
2 Biotech Stocks That Could Help Set You Up for Life
01:13pm, Saturday, 11'th Feb 2023
The two companies have seen similar share growth over the past year.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
06:35pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
05:00pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
03:04pm, Thursday, 09'th Feb 2023
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
11:45pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
ROP is a leading cause of childhood blindness worldwide
The 7 Best Biotech Stocks to Buy for February 2023
01:51pm, Tuesday, 07'th Feb 2023
While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility lar
Is Biotech Immunocore About To Make A 25% Price Move?
07:00am, Tuesday, 07'th Feb 2023
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc
